Substituted 1,2,3,4-tetrahydropyrido[3,4-e] pyrrolo[1,2-a]pyrimidines as kinase inhibitors

A compound represented by Formula I, its enantiomers, diastereoisomers, tautomers, or a pharmaceutically acceptable salt thereof:

• wherein:
• R1 is H or NR13aR14a;
• R2 is substituted or unsubstituted heterocyle or is substituted or unsubstituted aryl;
• R3 is substituted or unsubstituted heterocyle or is substituted or unsubstituted aryl;
• R4 is H or NR13aR14a;
• R5 is H or substituted or unsubstituted C1-8 alkyl;
• R6 is H or substituted or unsubstituted C1-8 alkyl;
• R7 is H or substituted or unsubstituted C1-8 alkyl;
• R8 is H or substituted or unsubstituted C1-8 alkyl;
• R9 is H or substituted or unsubstituted C1-8 alkyl;
• R10 is H or substituted or unsubstituted C1-8 alkyl;
• X is
• Y is CR11 or N;
• W is CR12 or N;
• R11 is hydrogen, halogen, C(O)OR17, CF3, C1 to C8 alkyl, NR13aR14a, C(O)NR13aR14a, (CR15R16)pNR13aR14a, (CR15R16)pC(O)OR17, (CR15R16)pOR17, NR13C(O)(CR15R16)pNR13aR14a, NR13C(O)(CR15R16)pC(O)OR17, NR13C(O)(CR15R16)pOR17, C(O)(CR15R16)pNR13aR14a, C(O)(CR15R16)pC(O)OR17, C(O)(CR15R16)pCOR17, C(O)NR13(CR15R16)pNR13R14, C(O)NR13(CR15R16)pC(O)OR17, C(O)NR13(CR15R16)pCOR17, NR13C(O)NR14(CR15R16)pNR13R14, NR13C(O)NR14(CR15R16)pC(O)OR17, or NR13C(O)NR14(CR15R16)pOR17;
• R12 is hydrogen, halogen, C(O)OR17, CF3, C1 to C8 alkyl, NR13aR14a, C(O)NR13aR14a, (CR15R16)pNR13aR14a, (CR15R16)pC(O)OR17, (CR15R16)pOR17, NR13C(O)(CR15R16)pNR13R14, NR13C(O)(CR15R16)pC(O)OR17, NR13C(O)(CR15R16)pOR17, C(O)(CR15R16)pNR1a3R14a, C(O)(CR15R16)pC(O)OR17, C(O)(CR15R16)pCOR17, C(O)NR13(CR15R16)pNR13R14, C(O)NR13(CR15R16)pC(O)OR17, C(O)NR13(CR15R16)pCOR17, NR13C(O)NR14(CR15R16)pNR13aR14a, NR13C(O)NR14(CR15R16)pC(O)OR17, or NR13C(O)NR14(CR15R16)pOR17;
• R13 is H or substituted or unsubstituted C1-8 alkyl;
• R14 is H or substituted or unsubstituted C1-8 alkyl;
• R13a is H, substituted or unsubstituted C1-8 alkyl or together with R14a and the N can form a substituted or unsubstituted heterocycle;
• R14a is H, substituted or unsubstituted C1-8 alkyl or together with R13a and the N can form a substituted or unsubstituted heterocycle;
• R15 is H, halogen, hydroxyl, CF3 or substituted or unsubstituted C1-8 alkyl;
• R16 is H halogen, hydroxyl, CF3 or substituted or unsubstituted C1-8 alkyl;
• R17 is H or substituted or unsubstituted C1-8 alkyl;
• a is 0 or 1;
• and
• p is 1, 2, 3 or 4.